Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...
Akebia Therapeutics, Inc. (Nasdaq: AKBA), today announced that its collaboration partner, Japan Tobacco Inc. (JT), received approval from the...
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose of bettering the lives of people impacted by kidney disease,...
Akebia Therapeutics, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the ...
Akebia Therapeutics, Inc. (Nasdaq: AKBA), today announced the presentation of clinical data from its PRO2TECT global Phase 3 program that evaluated...
Akebia Therapeutics, Inc. (Nasdaq: AKBA) today announced the presentation of clinical data from its global INNO2VATE Phase 3 program, which...
Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced that it will present data from its global Phase 3 programs of vadadustat for the treatment...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.